Godrej Agrovet Limited — Q4 FY26 earnings call

Call held 4 May 2026

Management summary

Godrej Agrovet reported a strong Q4 FY26 and full-year FY26 performance, with consolidated revenues growing 9% YoY to INR2,333 crores and INR10,233 crores respectively. Profitability saw significant improvement, driven by volume-led growth, margin management, and a favorable business mix. While Animal Nutrition and Oil Palm segments performed well, Crop Care faced headwinds, and Creamline Dairy's profitability was pressured. The company is strategically shifting towards value-added products and consumer-centric models across its businesses, with a positive outlook for FY27 despite macro uncertainties.

Highlights

  • Q4 FY26 consolidated revenues grew 9% YoY to INR2,333 crores.

  • Q4 FY26 PBT (excluding non-recurring and exceptional items) increased 16.8% to INR87 crores.

  • FY26 consolidated revenues exceeded INR10,000 crores, reaching INR10,233 crores, representing a robust year-on-year growth of 9%.

  • FY26 PBT (excluding non-recurring and exceptional items) increased 17.2% year-on-year to INR569 crores.

  • Animal Nutrition delivered strong Q4 volumes, growing 15% year-on-year, with cattle feed volumes increasing sharply by 24%.

  • Astec LifeSciences achieved EBITDA break-even in fiscal year '26.

Concerns

  • Crop Care business remained impacted in Q4 FY26 due to carry forward of inventory.

  • Creamline Dairy profitability remained under pressure due to elevated milk procurement costs.

  • Uncertainty regarding the impact of El Niño on monsoon and the Iran war on palm oil prices and crop protection.

Key financials

2 periods

Headline

  • Consolidated Revenue
    ₹2,333 Cr
    YoY +9%
  • Consolidated PBT (excl. non-recurring/exceptional)
    ₹87 Cr
    YoY +16.8%

FY26

  • Consolidated Revenue
    ₹10,233 Cr
    YoY +9%
  • Consolidated PBT (excl. non-recurring/exceptional)
    ₹569 Cr
    YoY +17.2%
  • ROCE
    20%

What they filed

Q1 FY27: revenue up 9.9%, net profit up 8.9% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue1,848 1,869 1,550 2,007 2,000 +8%2,070 +11%1,668 +8%2,205 +10%
EBITDA222 195 130 259 196 −12%212 +9%105 −19%228 −12%
Net profit132 166 68 169 177 +34%116 −30%65 −4%184 +9%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Animal Nutrition
    15% Q4 Volume Growth24% Cattle Feed Volume Growth₹9.5 Cr Q4 Segment Margin Improvement
  • Oil Palm
    20.8% Q4 Oil Extraction Ratio60,000 tons Q4 FFB Processed6,37,000 tons Annual FFB Processed
  • Crop Care
    ₹0 Cr FY26 EBITDA
  • Creamline Dairy
    5% Q4 Revenue Growth (excl. bulk sales)40% Value-Added Product Salience
  • Godrej Foods
    80% FY26 Branded Revenue Salience

Capital allocation

high confidence
  • Capex ₹400 Cr
    • Growth capex
    • Oil palm business
    In terms of the cash flow, we expect that for the full year of FY '27, we will be sort of after taking care of the capex requirements of the year, which is close to INR400 crores, we should be left with around INR100 crores, INR125 crores kind of cash surplus which will be there. And in terms of capex, I think our capex requirements would be in the coming years we have pretty much first of all out of our overall capex would be in the range of around 350-odd crores. Roughly around 75% to 80% of that capex will be growth capex for us. ... roughly around I think 50-odd percent of our capex deployment is going towards oil palm business.
  • Liquidity Cash ₹100 Cr Expected cash surplus after capex for FY27.
    In terms of the cash flow, we expect that for the full year of FY '27, we will be sort of after taking care of the capex requirements of the year, which is close to INR400 crores, we should be left with around INR100 crores, INR125 crores kind of cash surplus which will be there.

Guidance & targets

Revenue

  • Consolidated Revenue Growth Revenue · FY27 · Medium confidence early double-digit
    Overall, at a GAVL level, would like to look at we'd like to focus on getting an early double-digit revenue growth across put together at a consol level.

    — Sunil Kataria

  • Crop Care Revenue Growth Revenue · FY27 · Medium confidence very high double-digit
    Otherwise, we'll go for very strong recovery in both bottom line and top line and it will be again a very high double-digit numbers that will happen in the Crop Care business.

    — Sunil Kataria

  • Astec LifeSciences Top-line Growth Revenue · FY27 · Medium confidence 15%
    So I think we should aim around 15% of growth in terms of the top line.

    — Arijit Mukherjee

  • Astec LifeSciences Top-line Growth Revenue · FY27 · Medium confidence 20%
    But I believe we have a pretty good shot at something in the range of 20% kind of a number going forward on this.

    — Sunil Kataria

Profitability

  • Consolidated PBT Growth Profitability · FY27 · Medium confidence mid-strong double-digit, mid-teens
    Along with the way our PBT has improved this year, we'd like to again target a let's say a mid-strong double-digit, mid-teens kind of a PBT growth also for the next year.

    — Sunil Kataria

Volume

  • Oil Palm Volume Growth Volume · FY27 · Medium confidence early double-digit
    Again, looking for another year of double-digit volume growth in oil palm, early double-digit.

    — Sunil Kataria

Area Expansion

  • Oil Palm Area Expansion Area Expansion · FY27 · Medium confidence beating record
    Next year we're gunning for even beating that record on area expansion.

    — Sunil Kataria

Portfolio Mix

  • Oil Palm Value-Added Products as % of Portfolio Portfolio Mix · FY31 · Medium confidence 50-55%
    Our Broad direction is that we would like this business to have roughly around 50% to 55% of its portfolio over a period of maybe FY31 in that direction, if I had to put, coming out of value-added products.

    — Sunil Kataria

Capex

  • Capex Requirements Capex · FY27 · High confidence INR400 crores
    In terms of the cash flow, we expect that for the full year of FY '27, we will be sort of after taking care of the capex requirements of the year, which is close to INR400 crores

    — S. Varadaraj

Product Contribution

  • New Crop Care Products (Ashitaka, TAKAI) Contribution Product Contribution · FY27 · High confidence 16-18%

    Previously 3%16-18%

    Between these two products itself, if everything goes right in terms of weather, season, etcetera, don't play truant. We expect these two products itself to contribute roughly around anywhere between 16% to 18% of our business. So that's the kind of shift that we'll see roughly around a four times salience shifting for us that this thing that would happen for us next year.

    — Sunil Kataria

Market context

  • Animal Nutrition Revenue Growth Revenue · FY27 · Medium confidence double-digit
    We'd like to again go for a double-digit growth in revenue led by volume in Animal Nutrition business as we would like to call it now.

    — Sunil Kataria

What to watch in Q1 FY27

Crop Care Business Recovery

from quarter two onwards (Q2 FY27)
Current Impacted in Q4 FY26 due to inventory carry forward
Target Very strong recovery with very high double-digit growth

Why it matters

Recovery of this segment is key for overall growth and profitability, as it was impacted in the previous quarter.

Otherwise, we'll go for very strong recovery in both bottom line and top line and it will be again a very high double-digit numbers that will happen in the Crop Care business.

Risks & concerns

  • Iran War Impact on Commodity Prices

    medium

    The Iran war has made palm oil price models 'haywire' and could impact crop protection business negatively, while potentially benefiting oil palm.

    Management acknowledged

  • El Niño and Below-Normal Monsoon

    medium

    Predictions of a below-normal monsoon due to El Niño create uncertainty, though impact varies geographically and oil palm is less affected short-term.

    Management acknowledged

  • Elevated Milk Procurement Costs

    medium

    High milk procurement costs are pressuring Creamline Dairy's profitability, though management expects prices to cool down from Q2 FY27.

    Management acknowledged

Q&A highlights

6 direct
FY27 Outlook for Revenue Growth and Profitability Partial
Overall, at a GAVL level, would like to look at we'd like to focus on getting an early double-digit revenue growth across put together at a consol level. Along with the way our PBT has improved this year, we'd like to again target a let's say a mid-strong double-digit, mid-teens kind of a PBT growth also for the next year.

Analyst sought specific FY27 guidance, and management provided directional targets while acknowledging macro uncertainties like the Iran war.

Asked by Abhijit Akella

Palm Oil Business Outlook, Prices, and El Niño Impact Partial
So it's very, very difficult to give you a very long-term point of view, but I would say we'll take it by the quarter. And maybe I'll ask NBG, if NBG wants to also give any sense of what his take on this is right now. Mr. Godrej, would you like to? ... Yes, so we feel that there will not be a very bad impact on oil palm this year even if the monsoon is poor, because oil palm being a tree, it takes a long time to get affected.

Analyst probed on the impact of El Niño and volatile palm oil prices, to which management indicated short-term uncertainty but long-term resilience due to the nature of oil palm and internal 'demographic dividend'.

Asked by Abhijit Akella

Astec LifeSciences Management Restructuring and Future Strategy Direct
Yes, hi Abhijit, this is Burjis speaking. I just want to say that we do believe that Astec has very strong underlying potential and this is supported by Godrej Industries Group's very deep chemical experience and manufacturing expertise. So we did make some recent management and Board changes which reflect our intent to leverage this expertise more effectively and accelerate value creation and synergies.

Analyst inquired about the recent management changes at Astec, and management clarified the strategic intent to leverage group expertise and accelerate growth, with a focus on CDMO.

Asked by Abhijit Akella

Animal Feed Volume Growth Drivers and Margins Direct
So I think on the animal nutrition business, I think it's a mix of some very, very strong execution which has been happening and some environmental support. So the one, let me first say the little bit part of the environmental support, I would not say that played the biggest role, is the fact that as when milk procurement prices remain so elevated, it does become a kind of a positive trigger for shift from unbranded to branded compound feed business because the farmers see the benefits of the income which they're generating from a better higher milk yield.

Analyst sought reasons for accelerated volume growth and margin stability in animal feed, and management detailed execution improvements, new product launches, and a positive environmental factor (high milk prices).

Asked by Abhijit Akella

Astec Raw Material Sourcing from China and Currency Depreciation Impact Direct
Look, in our sort of businesses, currency management or currency volatility is a part of a structurally we approach to it, right? But you have to remember that we are a net exporter. So once ever the depreciation happens and the export realization actually offers a natural hedge to the imports.

Analyst questioned the impact of China sourcing (47% of imports) and currency depreciation, and management explained that being a net exporter provides a natural hedge.

Asked by Maneesh Bhadane

Crop Care New Product Launches and Diversification Strategy Direct
Now, one thing which is going to shift drastically over the next 5 years is that we are diversifying our portfolio very sharply. Obviously, products take time to come out of this, but we are going to move away from two crop segment product to a multi-crop segment product company. ... One is something which got launched in the month of December last year, which is Ashitaka, which is our first maize entry, which is a maize herbicide. ... The second is we are entering into a rice plus insecticide segment through a product which is called TAKAI, which is actually a multi-crop insecticide, although its lead application is paddy.

Analyst asked about new product launches in Crop Care, and management detailed a significant strategic shift towards multi-crop diversification with specific new products (Ashitaka, TAKAI) expected to drive substantial growth.

Asked by Sumant Kumar

Strategic Direction and Value Creation for GAVL Direct
But I hear your question loud and clear that, what is it that you're seeing? And first of all, thank you for noting down some of the shifts that we're making. So one fundamental piece over the next two years what you can expect is that the one, see any transformation takes four-five years to happen fully. And specially in a business like us which is a multi-segmental business. But the shift that you'll start seeing in the from -- already started panning out in the next two years is that, we will move from fundamentally from a commodity-centric thinking to a market-customer facing approach, whatever the nature of the entity itself is right now.

Analyst sought clarity on GAVL's strategic direction for the next two years, and management outlined a fundamental shift from commodity-centric to market-customer facing, emphasizing innovation and value-added products across segments.

Asked by Aejas Lakhani

Future of Live Birds Business and Frozen Chicken Strategy Direct
So, one thing is live trading per se is coming down sharply for us and over this next four-five-year period and I think more accelerated manner, we would not be in the business of selling live birds. That is very clear. That trading we don't want to do. ... Now, what is happening in this business is that there is a potential of doing a category creation altogether in this business. That one of the reasons why fresh chicken never sold was because there's a shelf life of four days. Now, with frozen chicken, the shelf life changes.

Analyst questioned the future of the live birds business, and management confirmed a strategic exit from live bird trading to focus on value-added products like frozen chicken, leveraging quick commerce for category creation.

Asked by Probal Sen

3 min read 7 chapters

Detailed narrative

Q4 FY26 and Full Year Performance Overview

Godrej Agrovet delivered a strong Q4 FY26, with consolidated revenues growing 9% year-on-year to INR2,333 crores. Profit before tax (excluding non-recurring and exceptional items) increased 16.8% to INR87 crores. For the full fiscal year 2026, the company surpassed INR10,000 crores in consolidated revenues, reaching INR10,233 crores, a 9% year-on-year growth. Full-year PBT (excluding non-recurring and exceptional items) increased 17.2% year-on-year to INR569 crores, reflecting improved earnings quality and margin expansion.

Strategic Shift Towards Value-Added and Consumer-Centric Models

The company is undergoing a fundamental strategic shift from a commodity-centric to a market-customer facing approach across all its businesses. This involves moving Animal Nutrition from a feed business to a nutrition mindset, Crop Care from product chemistry to product innovation and branding, and Oil Palm from a volume-led upstream player to a full-fledged value-added player. This transformation is expected to accelerate over the next two years, with full realization over four to five years, aiming for more consistent revenue growth and improved ROCE.

Segmental Performance and Outlook

Animal Nutrition showed strong Q4 volumes, up 15% YoY, with cattle feed volumes increasing 24%, driven by new products and cost optimization. The Oil Palm business achieved record area expansion and high oil extraction ratios, with plans to beat this record in FY27 and grow value-added products to 50-55% of its portfolio by FY31. Crop Care was impacted in Q4 by inventory carry-forward but is expected to see a 'very strong recovery' with 'very high double-digit numbers' from Q2 FY27, driven by new product launches like Ashitaka and TAKAI.

Astec LifeSciences Turnaround and Growth Strategy

Astec LifeSciences achieved EBITDA break-even in FY26, demonstrating strong turnaround momentum. Q4 saw robust revenue and EBITDA growth, driven by higher CDMO volumes, improved realizations, and better capacity utilization. The company aims for 15-20% top-line growth in FY27, with a continued focus on CDMO-led expansion. Recent board augmentations, including Mr. Vishal Sharma as Non-Executive Chairperson and Mr. Arijit Mukherjee as Executive Director, are expected to strengthen leadership and accelerate growth by leveraging Godrej Industries Group's chemical expertise.

Capital Allocation and Shareholder Returns Focus

Godrej Agrovet plans approximately INR400 crores in capex for FY27, with 75-80% dedicated to growth initiatives, including about 50% for the oil palm business. Despite this investment, the company expects a cash surplus of INR100-125 crores for FY27. Management emphasized a commitment to a consistent dividend policy, historically in the 48% payout range, and highlighted a significant improvement in Return on Capital Employed (ROCE) from 16% to 20% in FY26 due to disciplined working capital management.

New Product Pipeline and Diversification

In Crop Care, the company is diversifying its portfolio beyond cotton herbicide, with new products like Ashitaka (maize herbicide) and TAKAI (rice plus insecticide) launched. These are expected to contribute 16-18% of the business in FY27, up from ~3% in FY26. In the Foods business, new entries into momos and frozen chicken are planned, with a strategic move away from the live bird trading business to focus on value-added, branded offerings. This aims to create new categories and insulate the business from commodity price volatility.

Macroeconomic Risks and Mitigation Strategies

Management acknowledged potential impacts from the Iran war, which could affect palm oil prices positively and crop protection negatively, and predictions of a below-normal monsoon due to El Niño. They noted that the El Niño's impact is geographically and temporally variable, with oil palm being less affected short-term. Mitigation strategies include internal interventions, leveraging the 'demographic dividend' in oil palm (maturing juvenile trees), and the strategic shift towards value-added products to insulate from price volatility.

This is an AI-generated summary of a publicly available earnings call transcript.